Objective
PRECIOUS aims at scaling-up biodegradable nanomedicines for multimodal precision cancer immunotherapy.
With 3.5 million cancer patients in Europe every year, new cancer medicines are eagerly awaited, notably for prostate and ovarian cancer.
Systemically applied new immunotherapies are promising, but their toxicity is a hurdle. Vaccination against cancer is safe but rather the efficacy can be disappointing, i.e. the microenvironment shuts down anti-tumour immunity.
PRECIOUS will tackle 2 bottlenecks:
1. Production of non toxic multimodal nanomedicines, which induce vigorous immune responses, and at the same time reverse immunosuppression
2. Large scale GMP production of nanomedicines, and initiate a multimodal immunotherapy Phase I trial.
We want to solve these bottlenecks by:
Objective 1: Two types of GMP biodegradable nanoparticles: 1) a nanovaccine, containing tumour antigens and immune activators, and 2) a nanoparticle composed of compounds, which reverses the suppression and reactivates immunity in the tumour.
Objective 2: Clinical Phase I trial to show efficacy. Nanomedicines will be used by 1) injection of vaccines to evoke immune responses and 2) injection of nanoparticles in the tumour microenvironment, which slowly release compounds that reverse suppression.
To achieve this, a platform is formed with 6 leading industrial partners to produce large scale GMP nanomedicines and an excellent immunomodulator track record, together with 5 renowned academic partners to perform clinical studies.
Relevance to call: Large scale GMP production, industrial leadership, nanotechnology and advanced manufacturing KET technologies, translation to the clinic, marketing development.
Fields of science
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesclinical medicineoncology
- engineering and technologynanotechnologynano-materials
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Programme(s)
Funding Scheme
RIA - Research and Innovation action
Coordinator
6525 GA Nijmegen
Netherlands
See on map
Participants (11)
45128 Essen
See on map
6041 Gosselies
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
WC2R 1DJ London
See on map
02-089 Warszawa
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1117 BM Schiphol
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
78464 Konstanz
See on map
162 06 Praha 6
See on map
OX1 2JD Oxford
See on map
20133 Milan
See on map
3584 BL Utrecht
See on map
Participation ended
6525 XZ Nijmegen
See on map